Investigating IL‐33 in the context of the liver cancer microenvironment might unveil innovative immunotherapeutic strategies or elucidate resistance mechanisms to current therapies, marking a promising frontier for exploration in cancer biology. This evidence concerns the gene IL33 and cancer.